title: Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment.
authors.forename: Francesco
authors.initials: F
authors.lastname: Pantano
authors.forename: Francesco Maria
authors.initials: FM
authors.lastname: Guida
authors.forename: Caterina
authors.initials: C
authors.lastname: Vivaldi
authors.forename: Bruno
authors.initials: B
authors.lastname: Vincenzi
authors.forename: Enrique
authors.initials: E
authors.lastname: Grande
authors.forename: Mercedes Rodriguez
authors.initials: MR
authors.lastname: Garrote
authors.forename: Michele
authors.initials: M
authors.lastname: Caraglia
authors.forename: Nicola
authors.initials: N
authors.lastname: Silvestris
authors.forename: Enrico
authors.initials: E
authors.lastname: Vasile
authors.forename: Gianluca
authors.initials: G
authors.lastname: Masi
authors.forename: Alfredo
authors.initials: A
authors.lastname: Falcone
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Tonini
authors.forename: Daniele
authors.initials: D
authors.lastname: Santini
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D001786:Blood Glucose; D015992:Body Mass Index; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D001786:Blood Glucose; D000068818:Cetuximab
keywords: FBG; TTP; anti-EFGR; body mass index; cancer; cetuximab; colorectal cancer